Hospital-acquired Antibiotic-resistant Fungal Infections Being Tackled by Torrance, CA Non-profit

Monday, April 15, 2019
Investigator(s)
Ashraf Ibrahim, PhD
Jack Edwards Jr., MD
Fungus enlarged with microscope

Researchers at LA BioMed in Torrance, CA have been working to create a therapeutic vaccine for 2 years to fight infections caused by Candida auris. The lab studies have been most encouraging. With its resistance to anti-fungal drugs, a vaccine is likely the best way to combat the antibiotic-resistant nature of this emerging and deadly pathogen.

Drs. Ashraf Ibrahim and Jack Edwards, in conjunction with the LA BioMed spinoff company NovaDigm Therapeutics, are developing a vaccine specifically designed to combat these infections, largely hospital acquired, and very often fatal.  Recent media coverage documents the necessity of exactly this type of non-antibiotic approach.

 

About The Lundquist Institute: "Research with Reach"™

The Lundquist Institute is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases. Find out more at https://lundquist.org.